Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | MMP13 | P45452 | 19/20 | 0.52 |
| ▸ | MMP2 | P08253 | 4/20 | 0.52 |
| ▸ | MMP8 | P22894 | 4/20 | 0.52 |
| ▸ | MMP9 | P14780 | 17/20 | 0.51 |
| ▸ | MMP1 | P03956 | 15/20 | 0.51 |
| ▸ | ADAM17 | P78536 | 10/20 | 0.51 |
| ▸ | MMP3 | P08254 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26027425 | 0.89 | MMP13 (0.63) | CYP3A4CYP2C9PKMCYP2C19MMP13 | |
| SCHEMBL25315242 | 0.86 | CYP3A4 (0.50) | CYP3A4CYP2C9PKMCYP2C19MMP13 | |
| SCHEMBL25317994 | 0.82 | RAB9A (0.40) | CYP3A4CYP2C9PKMCYP2C19MMP13 | |
| SCHEMBL30507123 | 0.82 | RAB9A (0.40) | CYP3A4CYP2C9PKMCYP2C19MMP13 | |
| SCHEMBL23049642 | 0.77 | CYP3A4 (0.58) | CYP3A4CYP2C9PKMCYP2C19MMP13 | |
| SCHEMBL25316944 | 0.77 | PKM (0.61) | CYP3A4CYP2C9PKMCYP2C19MMP13 | |
| SCHEMBL8334812 | 0.76 | MMP13 (0.61) | CYP3A4CYP2C9PKMCYP2C19MMP13 | |
| SCHEMBL4004910 | 0.76 | CYP3A4 (0.60) | CYP3A4CYP2C9PKMCYP2C19MMP13 | |
| SCHEMBL23049636 | 0.75 | CYP3A4 (0.56) | CYP3A4CYP2C9PKMCYP2C19MMP13 | |
| SCHEMBL6264143 | 0.73 | ADAM17 (0.78) | MMP13MMP2MMP9MMP1ADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282781-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2025-09-11 | — | — | US | disclosed |
| US-12344610-B2 | APOL1 inhibitors and methods of use | MAZE THERAPEUTICS, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| WO-2024249254-A2 | METHODS OF USING APOL1 INHIBITORS | MAZE THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| US-20240400565-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2024-12-05 | — | — | US | disclosed |
| EP-4465982-A2 | APOL1 INHIBITORS AND METHODS OF USE | Maze Therapeutics, Inc. (US) | 2024-11-27 | — | — | EP | disclosed |
| US-11976067-B2 | APOL1 inhibitors and methods of use | MAZE THERAPEUTICS, INC. (US) | 2024-05-07 | — | — | US | disclosed |
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
| WO-2023141432-A2 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023141432-A2 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, LDLR | CYP3A4 1435/4885CYP2C9 2804/4885PKM 2565/4885 |
| US-12344610-B2 | APOL1 inhibitors and methods of use | APOL1, APOB, PON1 | CYP3A4 1340/4885CYP2C9 2790/4885PKM 2674/4885 |
| US-11976067-B2 | APOL1 inhibitors and methods of use | APOL1, APOB, LDLR | CYP3A4 1435/4885CYP2C9 2804/4885PKM 2565/4885 |
| US-20250282781-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, PON1 | CYP3A4 1340/4885CYP2C9 2790/4885PKM 2674/4885 |
| US-20240400565-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, PON1 | CYP3A4 1340/4885CYP2C9 2790/4885PKM 2674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.